Please login to the form below

Not currently logged in

Jonathan Fox leaves AstraZeneca for MyoKardia

Will lead programme to target genetic heart disease

Jonathan Fox, MyoKardiaMyoKardia has appointed former VP, clinical development at AstraZeneca Jonathan Fox to chief medical officer.

In his new role, Dr Fox will lead the development of the US biopharma's pipeline of small molecule therapeutics that focus on the treatment of genetic cardiovascular disease.

It's an area that Dr Fox has great experience, having served as senior director, clinical cardiovascular research at Merck & Co and director of clinical pharmacology at SmithKline Beecham, in addition to his time at AstraZeneca.

On top of this industry experience, Dr Fox has been a clinical professor of medicine at the University of Pennsylvania's School of Medicine for the past two decade.

He also served for four years as the industry representative to the FDA's Cardiovascular and renal Drug Products Advisory Committee.

Commenting on his appointment, he highlighted MyoKardia's potential in treating genetic heart disease.

“MyoKardia's genetically targeted approach and cutting-edge platform has the potential to fundamentally change the lives of patients with hypertrophic cardiomyopathy and dilated cardiomyopathy,” he said.

“By translating the groundbreaking science of the founding investigators into effective, disease modifying treatments, we may ultimately transform the future of treating cardiovascular disease.”

1st February 2013


Featured jobs

Subscribe to our email news alerts


Add my company
EY Life Sciences

Our global reach Against a backdrop of regulatory, digital, financial and global transformation, Life Sciences companies are finding integration and...

Latest intelligence

Waking the sleeping giant
The lights are coming on for healthcare delivery in Africa...
How to get rep buy-in for multi-channel
How do you manage a team who may be resistant to change?...
Blog: Digital therapeutics: within our reach?
Digital therapeutics is a hot topic right now. By using digital technology to manage, treat or even prevent chronic conditions, digital therapeutics is promising to revolutionise healthcare. But is this...